Korea Investment Corp
ALNY icon

Korea Investment Corp’s Alnylam Pharmaceuticals ALNY Stock Holding History

Korea Investment Corp’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.6M Buy
247,660
+47,339
+24% +$14.3M 0.14% 126
2026
Q1 		$66.3M Buy
200,321
+10,552
+6% +$3.59M 0.14% 142
2025
Q4 		$75.5M Sell
189,769
-7,143
-4% -$3.16M 0.15% 122
2025
Q3 		$89.8M Buy
196,912
+86,057
+78% +$35M 0.18% 98
2025
Q2 		$36.1M Buy
110,855
+5,096
+5% +$1.41M 0.08% 240
2025
Q1 		$28.6M Buy
105,759
+12,156
+13% +$3.12M 0.07% 276
2024
Q4 		$22M Sell
93,603
-14,290
-13% -$3.76M 0.05% 332
2024
Q3 		$29.7M Sell
107,893
-4,490
-4% -$1.17M 0.07% 274
2024
Q2 		$27.3M Buy
112,383
+73,220
+187% +$11.6M 0.07% 268
2024
Q1 		$5.85M Buy
39,163
+6,067
+18% +$1.01M 0.01% 552
2023
Q4 		$6.33M Buy
33,096
+35
+0.1% +$5.96K 0.02% 536
2023
Q3 		$5.86M Sell
33,061
-5,854
-15% -$1.12M 0.02% 481
2023
Q2 		$7.39M Buy
38,915
+1,656
+4% +$328K 0.02% 441
2023
Q1 		$7.46M Buy
37,259
+1,116
+3% +$235K 0.02% 458
2022
Q4 		$8.59M Sell
36,143
-20,987
-37% -$4.48M 0.03% 455
2022
Q3 		$11.4M Buy
57,130
+1,921
+3% +$366K 0.04% 397
2022
Q2 		$8.05M Sell
55,209
-6,414
-10% -$910K 0.02% 468
2022
Q1 		$10.1M Sell
61,623
-1,439
-2% -$219K 0.02% 442
2021
Q4 		$10.7M Buy
63,062
+39,762
+171% +$7.39M 0.03% 381
2021
Q3 		$4.4M Sell
23,300
-1,100
-5% -$206K 0.01% 537
2021
Q2 		$4.14M Sell
24,400
-200
-0.8% -$29.3K 0.01% 567
2021
Q1 		$3.47M Sell
24,600
-8,100
-25% -$1.22M 0.01% 579
2020
Q4 		$4.25M Buy
32,700
+400
+1% +$53.4K 0.01% 538
2020
Q3 		$4.7M Buy
32,300
+2,500
+8% +$355K 0.02% 439
2020
Q2 		$4.41M Buy
29,800
+2,100
+8% +$283K 0.02% 454
2020
Q1 		$3.02M Buy
+27,700
New +$3.2M 0.01% 486
2018
Q3 		– Sell
-9,302
Closed -$916K – 696
2018
Q2 		$916K Hold
9,302
– – ﹤0.01% 653
2018
Q1 		$1.11M Buy
+9,302
New +$1.2M 0.01% 601

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Korea Investment Corp's ALNY Position: Q2 2026 in Review

Korea Investment Corp increased its Alnylam Pharmaceuticals (ALNY) stake by 24% in Q2 2026, buying an estimated $14.3M and bringing the position to 247,660 shares worth $74.6M. The position accounts for 0.14% of the portfolio, ranked #126.

Korea Investment Corp first reported a position in ALNY in Q1 2018 and has held it in 28 quarters since. The position peaked at $89.8M in Q3 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Korea Investment Corp held 247,660 shares of Alnylam Pharmaceuticals worth $74.6M as of Q2 2026.
  • Korea Investment Corp bought 47,339 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $14.3M.
  • Alnylam Pharmaceuticals made up 0.14% of Korea Investment Corp's portfolio in Q2 2026, its #126 holding.
  • Korea Investment Corp first reported a position in Alnylam Pharmaceuticals in Q1 2018 and has held it in 28 quarters since.
  • Korea Investment Corp's Alnylam Pharmaceuticals position peaked at $89.8M in Q3 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Korea Investment Corp's 13F filing for Q2 2026, filed 12 Aug 2026.